Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| HTR 07-128384-111 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will evaluate the primary irritation potential of NatrOVA Creme Rinse - 1% in humans, after exposure to UV radiation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | NatrOVA Creme Rinse - 1% |
|
| 2 | Experimental | NatrOVA Creme Rinse Vehicle Only |
|
| 3 | Placebo Comparator | Blank patch |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Spinosad (the active ingredient in NatrOVA) | Drug | This is a patch test in which the test material is applied to the patch and the patch applied to the skin. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety endpoint will be visual grading of UV irradiated test sites and assessments of adverse experiences | 7 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| John V Murray, MD | Hill Top Research | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hill Top Research | St. Petersburg | Florida | 33710 | United States |
Not provided
| Label | URL |
|---|---|
| sponsor web site | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| C415329 | spinosad |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| placebo | Drug |
|